New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
Nexgen Biofuels LTD (NXGN)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for Laxai Pharma Ltd
Additional Recent Accounting Pronouncements
Agenda
Alternate Directors
Amendment Memorandum Articles Association Allow Election New Directors
American Appraisal Valuation
Annex
Application Israeli Court
Approval Proposed Arrangement Pursuant 350 Law
Assumptions Limiting Conditions
Background Arrangement
Biodiesel Process
Biodiesel Production Plants Construction Expansion 2007
Biotechnology Researchers Danyel Wwwdanyelcoil
Boas Valuation Report
Business Activity
Business Adversely Affected Loses Services Key Personnel Depends
Business Nexgen
Business Strategy
Capital Gains Tax Applicable Shareholders
Certificate Appraiser
Chemag Consortium
Compared 2002
Compared 2003
Compensation Individual Directors
Competition
Conclusion
Conditions Closing
Consolidated Financial Statements
Construction Agreements Permits
Consultants Service Suppliers
Controlling Shareholders Limit Ability Influence Outcome Matters Requiring
Customers
Danyel
Dependent Independent Sales Agents Distributors Dealers
Directors Compensation
Directors Executive Officers Following Closing
Effectiveness Arrangement
Election New Directors
Eliezer Helfan
Evaluation Disclosure Controls Procedures
Excess Obsolete Inventory
External Directors
Fair Value
Fairness Arrangement Remaining Shareholders
Financial Information Highlights Healthcare 2006
Financial Information Highlights Healthcare Periods 2007
Financial Information Highlights Nexgen Period 2007 2006
Financing Arrangements
Foreign Currency Exchange Risk
Form 20-f
Form 8-k
Founded 1896
Funds
Future Acquisitions Absorb Significant Resources Unsuccessful
Gamida Group
Gamida Transaction
Gamidor Group
General
Genomics Industry Intensely Competitive Evolving
Goodwill Other Identifiable Intangibles
Grounds Application
Guarantees Payment Mac
Healthcare Technologies
History Nature Businesses
Important Events Development Business
Important Facilities Resources Located Israel Historically Experienced Military
Indemnification Arrangements Among Parties Purchase Agreement
Index
Industry Background
Interest Rate Risk
Interested Party Requirements
Interests Certain Parties Arrangement
Introduction
Introduction Summary
Inverness Letters Court Filings
Investor Not Rely Investment Such Requires Dividend Income
Israel Amir
Israeli Tax Considerations
Legal Proceedings
Mac Bioventures Inc
Major Suppliers
Manufacturing Savyon Wwwsavyondiagnosticscom
Market Opportunities
Marketing Sales Israel
Marketing Sales Worldwide Savyon
Matters Relating Extraordinary General Meeting
Nacbo Project
Need Strategic Partners Successful
Nexgen Biofuels
Nexgen Transaction
Nexgens Option
Not Receive Certain Regulatory Approvals Permitted Sell Products
Notice Extraordinary Meeting Shareholders
Objection Application Approval Plan Arrangement
Office Chief Scientist Ocs
Pages
Part Attention Additional Matters
Part Case Objection Premature Proper Place Raise Not
Part Plan Arrangement Benefits Shareholders Claims Discrimination Raised
Party Product Distribution Activities
Patents
Patents Not Protect Products Competition
Plan Operations Until Plant Start-up
Price Sales Products Limited Health Insurance Coverage Government
Principal Capital Expenditures Divestitures
Procognia
Product Development Marketing Operations
Product Sells Results Injury User Subject Liability Exposure
Professor Ethan Rubinstein
Proposed Transaction Immvarx Not Completed Successful
Provisions Israeli Law Delay Prevent Make Difficult Acquisition
Proxy Properly Executed Voted Directed Herein Please Sign
Purpose Shareholders Meeting
Purposes
Purposes Reasons Arrangement
Record Date Shares Entitled Vote
Report Independent Registered Public Accounting Firm
Research Development Grants
Research Developments Savyon
Response Healthcare Objection Arrangement
Risk Factors
Risks Related Financing Construction Development Facilities
Risks Related Government Regulation
Risks Related Operations Israel
Risks Related Ordinary Shares
Risks Related Ownership Shares Following Arrangement
Risks Relating Operations Israel
Sale Certain Distribution Activities
Sale Procognia
Sale Restricted Shares Cause Market Price Ordinary Drop
Sales
Savyon
Savyon Transaction
Scope Appraisal Data Received
Security Ownership Certain Beneficial Owners
Security Ownership Certain Beneficial Owners Following Closing Arrangement
Selected Financial Data
Selected Financial Data Nexgen
Shares Price Been Continue Volatile Result Substantial Losses
Significant Percentage Subsidiaries Products Dependent Certain Principal Suppliers
Sole Transaction Shall Shortly Brought Before Meeting Shareholders
Solicitation Proxies
Source Funds
Special Provisions Relating Measurement Taxable Income
Statutory Corporate Tax Rate
Stock Options
Sub-lease Arrangements
Subsidiaries Affiliates
Summary Arrangement
Summary Factors Influencing Audit Committee Board Directors
Summary Purchase Agreement
Summary Reasons Objection
Suppliers
Swot Analysis
Table Contents Proxy Statment
Tax Reform
Taxation Non-resident Shareholders Ordinary Income
Technology Products Genetic Screening Testing
Termination Purchase Agreement
Terms Office
Time Date Place
Transactions Interested Parties
Valuation Introduction
Vote Required
Voting
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour